Raynaud syndrome.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000328:Adult; D000792:Angiography; D000974:Antibodies, Antinuclear / Q000276:immunology; D001157:Arterial Occlusive Diseases / Q000150:complications; D001172:Arthritis, Rheumatoid / Q000150:complications; D001761:Bleomycin / Q000009:adverse effects; D001794:Blood Pressure; D001809:Blood Viscosity; D003080:Cold Temperature; D003276:Contraceptives, Oral / Q000009:adverse effects; D005260:Female; D006145:Guanethidine / Q000627:therapeutic use; D006225:Hand / Q000098:blood supply*; D006801:Humans; D008161:Lumbosacral Region; D008180:Lupus Erythematosus, Systemic / Q000150:complications; D008297:Male; D008875:Middle Aged; D008947:Mixed Connective Tissue Disease / Q000150:complications; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011928:Raynaud Disease / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D012039:Regional Blood Flow; D012110:Reserpine / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000150:complications; D013562:Sympathectomy; D013919:Thromboangiitis Obliterans / Q000150:complications; D014465:Ultrasonics; D014657:Vasculitis / Q000150:complications
D000319:Adrenergic beta-Antagonists; D000974:Antibodies, Antinuclear; D003276:Contraceptives, Oral; D010643:Phenoxybenzamine; D001761:Bleomycin; D012110:Reserpine; D006145:Guanethidine